A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2017
At a glance
- Drugs Diphencyprone (Primary)
- Indications Warts
- Focus Therapeutic Use
- Sponsors RXi Pharmaceuticals
- 06 Sep 2017 Status changed from recruiting to active, no longer recruiting, according to an RXi Pharmaceuticals Corporation media release.
- 11 May 2017 According to a RXi Pharmaceuticals media release, the company expects early read-outs in the second half of 2017.
- 13 Dec 2016 According to a RXi Pharmaceuticals media release, the read-out of the first cohort data will happen in the first half of 2017, the complete readout of the final study is anticipated in the second half of 2017.